Indian stocks: Visit www.stage2stocks.com →

MIRA Pharmaceuticals, Inc.

Stage 4 · Declining · week 35

As of Oct 22, 2026, MIRA Pharmaceuticals is in Stage 4, the downtrend phase, now in week 35 (since Feb 18, 2026). It closed at $0.63, 63.0% below its 52-week high and below its 200-day average, which is falling.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. More about the company

$0.63
-6.05% today
$26.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MIRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S? 39w
S4 15w
S2 14w
S4 35w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 39w → S4 9w → S1 3w → S2 7w → S3 9w → S2 5w → S3 2w → S4 15w → S1 6w → S2 14w → S3 5w → S2 11w → S3 4w → S4 35w current
Total tracked: 165 weeks across 14 stage runs.

MIRA among Drug Manufacturers - General18th of 21 by relative strength

All 21 →
Stocks in Drug Manufacturers - General ranked by relative strength, with stage and one-month change
#StockStageRS1M
1MRKStage 2 · wk 1692−0.6%
2BIIBStage 2 · wk 2192+11.6%
3LLYStage 2 · wk 190+13.5%
4AMGNStage 2 · wk 1687+10.1%
5OGNStage 2 · wk 2387+0.1%
6BMYStage 3 · wk 185+4.1%
7JNJStage 2 · wk 1683−0.6%
8PFEStage 2 · wk 877+7.9%
…18MIRAStage 4 · wk 3520−26.7%
vs 52W High
-63.0%
$0.61 lo$1.70 hi
63.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 35
1w13w26w
Week 35, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-36.6%
200 DMA: $0.99 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.14x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-26.7%
3M
-28.7%
6M
-40.1%
YTD
-57.8%
1Y
-56.6%
Scan Membership
Breakout Watch
Latest: 2025-06-26
3 appearances in last 60 days. First seen: 2024-08-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 35 · Vol 0.14x
2026-10-21S4
Wk 35 · Vol 0.18x
2026-10-20S4
Wk 34 · Vol 0.01x
2026-10-19S4
Wk 34 · Vol 0.09x
2026-10-16S4
Wk 34 · Vol 0.17x
2026-10-15S4
Wk 34 · Vol 0.18x
2026-10-14S4
Wk 34 · Vol 0.10x
2026-10-13S4
Wk 33 · Vol 0.09x
2026-10-12S4
Wk 33 · Vol 0.12x
2026-10-09S4
Wk 33 · Vol 0.07x
2026-10-08S4
Wk 33 · Vol 0.20x
2026-10-07S4
Wk 33 · Vol 0.09x
Moving averages & range
50 DMA
$0.76
200 DMA
$0.99
52W High
$1.70
52W Low
$0.61
5D Low
$0.63
Resistance levels (recent highs)
20d High
$0.90
60d High
$0.91
120d High
$1.16
250d High
$1.70
Next resistance
+43.6%
to 20d High
ROE
-217.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.2

MIRA Pharmaceuticals: quick answers

What stage is MIRA Pharmaceuticals in?

As of Oct 22, 2026, MIRA Pharmaceuticals (MIRA) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 18, 2026 and is in week 35. What the four stages mean

Is MIRA Pharmaceuticals in an uptrend?

No. MIRA Pharmaceuticals is in a Stage 4 downtrend. It trades 36.6% below its 200-day average, which is falling.

How far is MIRA Pharmaceuticals from its 52-week high?

MIRA Pharmaceuticals closed at $0.63 on Oct 22, 2026, 63.0% below its 52-week high of $1.70. Its 52-week low is $0.61.

How has MIRA Pharmaceuticals performed over the past year?

As of Oct 22, 2026, MIRA Pharmaceuticals is down 56.6% over the past year and down 57.8% so far in 2026.

Which sector and industry is MIRA Pharmaceuticals in?

MIRA Pharmaceuticals is in the Drug Manufacturers - General industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - General

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.